Temat: "Prostatic Neoplasms" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis.
Autorzy:: Fan A; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200030, China.
Li Y; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200030, China.
Zhang Y; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200030, China.
Meng W; Lab for Noncoding RNA and Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Pan W; Lab for Noncoding RNA and Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Chen M; Lab for Noncoding RNA and Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Ma Z; Lab for Noncoding RNA and Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China. .
Chen W; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200030, China. .; Pokaż więcej
Źródło:: Apoptosis : an international journal on programmed cell death [Apoptosis] 2024 Oct; Vol. 29 (9-10), pp. 1679-1695. Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:: Journal Article
MeSH Terms:: Coenzyme A Ligases*/genetics
Coenzyme A Ligases*/metabolism
Down-Regulation*/genetics
Down-Regulation*/drug effects
Ferroptosis*/genetics
Ferroptosis*/drug effects
Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/metabolism
Receptors, Androgen*/genetics
Receptors, Androgen*/metabolism
Nuclear Proteins*/genetics
Nuclear Proteins*/metabolism
Animals ; Humans ; Male ; Mice ; Benzamides/pharmacology ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Disease Progression ; Drug Resistance, Neoplasm/genetics ; Gene Expression Regulation, Neoplastic/drug effects ; Nitriles/pharmacology ; Phenylthiohydantoin/pharmacology ; Phenylthiohydantoin/analogs & derivatives ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/drug therapy ; Single-Cell Analysis

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 2.

Tytuł:: A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada.
Autorzy:: O'Sullivan DE; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada.
Kolinsky MP; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Shokar S; AstraZeneca Canada, Mississauga, Ontario, Canada.
Jarada TN; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada.
Cheung WY; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada. Electronic address: .; Pokaż więcej
Źródło:: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Oct; Vol. 22 (5), pp. 102115. Date of Electronic Publication: 2024 May 09.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Androgen Receptor Antagonists*/therapeutic use
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Humans ; Male ; Aged ; Retrospective Studies ; Alberta/epidemiology ; Middle Aged ; Aged, 80 and over ; Receptors, Androgen/metabolism ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/mortality ; Androgen Antagonists/therapeutic use

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 3.

Tytuł:: Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC).
Autorzy:: Custodio-Cabello S; Medical Oncology, Hospital Universitario De Torrejón, Madrid, Spain.
Pacheco-Barcia V; Medical Oncology, Hospital Universitario De Torrejón, Madrid, Spain.
Palka-Kotlowska M; Medical Oncology, Hospital Universitario De Torrejón, Madrid, Spain.
Fernández-Hernández L; Urology, Hospital Universitario de Torrejón, Madrid, Spain.
Del Álamo JF; Urology, Hospital Universitario de Torrejón, Madrid, Spain.
Oliveros-Acebes E; Internal Medicine, Hospital Universitario De Torrejón, Madrid, Spain.
Cabezón-Gutiérrez L; Medical Oncology, Hospital Universitario De Torrejón, Madrid, Spain; Faculty of Medicine, Francisco de Vitoria University, Pozuelo de Alarcón, Madrid, Spain. Electronic address: .; Pokaż więcej
Źródło:: Urologic oncology [Urol Oncol] 2024 Oct; Vol. 42 (10), pp. 331.e13-331.e24. Date of Electronic Publication: 2024 Jun 25.
Typ publikacji:: Journal Article
MeSH Terms:: Germ-Line Mutation*
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/pathology
Humans ; Male ; Prognosis ; Aged ; Middle Aged ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Aged, 80 and over ; Genetic Predisposition to Disease

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 4.

Tytuł:: Identification of blood lipid markers of docetaxel treatment in prostate cancer patients.
Autorzy:: Finnerty MC; Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA, 30602, USA.
Leach FE 3rd; Department of Chemistry, University of Georgia, Athens, GA, 30602, USA.; Complex Carbohydrate Research Center, University of Georgia, Athens, GA, 30602, USA.
Zakharia Y; Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, 52242, USA.; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242, USA.
Nepple KG; Department of Urology, University of Iowa, Iowa City, IA, 52242, USA.
Bartlett MG; Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA, 30602, USA.
Henry MD; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242, USA.; Department of Internal Medicine, University of Iowa, Iowa City, IA, 52242, USA.
Cummings BS; Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA, 30602, USA. .; Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48202, USA. .; Interdisciplinary Toxicology Program, University of Georgia, Athens, GA, 30602, USA. .; College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Sep 27; Vol. 14 (1), pp. 22069. Date of Electronic Publication: 2024 Sep 27.
Typ publikacji:: Journal Article
MeSH Terms:: Docetaxel*/therapeutic use
Docetaxel*/pharmacology
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/blood
Prostatic Neoplasms*/pathology
Lipidomics*/methods
Biomarkers, Tumor*/blood
Lipids*/blood
Humans ; Male ; Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Drug Resistance, Neoplasm ; Middle Aged ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/pathology ; Cell Line, Tumor ; Tandem Mass Spectrometry

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 5.

Tytuł:: Genomic Landscape in Prostate Cancer in a Latin American Population.
Autorzy:: Angel M; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina.
Freile B; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina.
Rodriguez A; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina.
Cayol F; Hospital Italiano de Buenos Aires, CABA, Argentina.
Manneh Kopp R; Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
Rioja P; Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú.
Soule T; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina.
Losco F; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina.
Bernal Vaca L; Instituto Nacional De Cancerología (Colombia), Bogotá, Colombia.
Penaloza JM; Centro Oncológico Integral, Neuquén, Argentina.
Zapata Muñoz ML; Clínica Las Américas Medellín, Antioquia, Colombia.
Neciosup SP; Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú.
Sanchez RR; Hospital Militar Central, Buenos Aires, Argentina.
Passarella C; Hospital Universitario Austral, Buenos Aires, Argentina.
Guerreño E; Instituto Misionero del Cáncer, Misiones, Argentina.
Farelluk D; Instituto Misionero del Cáncer, Misiones, Argentina.
Maturana Leiva E; Instituto del Cáncer Red Salud, Santiago de Chile, Chile.
Zarba M; Hospital Centro de Salud Zenón Santillán, Tucumán, Argentina.
Bourlon MT; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Mora Pineda M; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Sade JP; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina.; Pokaż więcej
Źródło:: JCO global oncology [JCO Glob Oncol] 2024 Sep; Vol. 10, pp. e2400072. Date of Electronic Publication: 2024 Sep 30.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Prostatic Neoplasms, Castration-Resistant*/mortality
Genomics*
Humans ; Male ; Retrospective Studies ; Aged ; Middle Aged ; Latin America/epidemiology ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/mortality ; High-Throughput Nucleotide Sequencing ; BRCA2 Protein/genetics ; Mutation ; Germ-Line Mutation

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 6.

Tytuł:: Single-cell analysis revealing the metabolic landscape of prostate cancer.
Autorzy:: Wang J; Department of Urologic Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.
Ding HK; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.; Institute of Urology, Anhui Medical University, Hefei 230001, China.; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230001, China.
Xu HJ; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.; Institute of Urology, Anhui Medical University, Hefei 230001, China.; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230001, China.
Hu DK; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.; Institute of Urology, Anhui Medical University, Hefei 230001, China.; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230001, China.
Hankey W; Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Chen L; Department of Geriatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Xiao J; Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Liang CZ; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.; Institute of Urology, Anhui Medical University, Hefei 230001, China.; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230001, China.
Zhao B; Department of Geriatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Xu LF; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.; Institute of Urology, Anhui Medical University, Hefei 230001, China.; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230001, China.; Pokaż więcej
Źródło:: Asian journal of andrology [Asian J Androl] 2024 Sep 01; Vol. 26 (5), pp. 451-463. Date of Electronic Publication: 2024 Apr 23.
Typ publikacji:: Journal Article
MeSH Terms:: Single-Cell Analysis*/methods
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/genetics
Male ; Humans ; Tumor Microenvironment ; Mitochondria/metabolism ; Prostate/metabolism ; Prostate/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/genetics ; Epithelial Cells/metabolism

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 7.

Tytuł:: Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting.
Autorzy:: Wenzel M; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Hoeh B; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Wagner N; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Koll F; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Siech C; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Humke C; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Steuber T; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Graefen M; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.; Department of Urology, Koc University Hospital, Istanbul, Turkey.
Kluth L; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Traumann M; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Banek S; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Chun FKH; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Mandel P; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.; Pokaż więcej
Źródło:: Journal of the American Geriatrics Society [J Am Geriatr Soc] 2024 Sep; Vol. 72 (9), pp. 2700-2708. Date of Electronic Publication: 2024 Jun 26.
Typ publikacji:: Journal Article
MeSH Terms:: Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Prostatic Neoplasms, Castration-Resistant*/mortality
Humans ; Male ; Aged ; Aged, 80 and over ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/mortality ; Docetaxel/therapeutic use ; Age Factors ; Neoplasm Metastasis ; Treatment Outcome ; Antineoplastic Agents/therapeutic use ; Retrospective Studies ; Survival Rate ; Androgen Receptor Antagonists/therapeutic use

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 8.

Tytuł:: Combination of Blood Adiponectin and Leptin Levels Is a Predictor of Biochemical Recurrence in Prostate Cancer Invading the Surrounding Adipose Tissue.
Autorzy:: Suzuki A; Morphological Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama 241-8515, Kanagawa, Japan.; Department of Urology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.
Sato S; Morphological Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama 241-8515, Kanagawa, Japan.; Department of Pathology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.; Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama 241-8515, Kanagawa, Japan.
Nakaigawa N; Department of Urology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.
Kishida T; Department of Urology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.
Miyagi Y; Department of Pathology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.; Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama 241-8515, Kanagawa, Japan.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Aug 17; Vol. 25 (16). Date of Electronic Publication: 2024 Aug 17.
Typ publikacji:: Journal Article
MeSH Terms:: Adiponectin*/blood
Leptin*/blood
Neoplasm Recurrence, Local*/blood
Neoplasm Recurrence, Local*/pathology
Adipose Tissue*/metabolism
Adipose Tissue*/pathology
Prostate-Specific Antigen*/blood
Prostatic Neoplasms*/blood
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/surgery
Humans ; Male ; Aged ; Middle Aged ; Retrospective Studies ; Biomarkers, Tumor/blood ; Prognosis ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Exploring potential therapeutic combinations for castration-sensitive prostate cancer using supercomputers: a proof of concept study.
Autorzy:: Tomić D; Centre for Informatics and Computing, Rudjer Boskovic Institute, 10000, Zagreb, Croatia. .
Murgić J; Department of Oncology and Nuclear Medicine, Sisters of Charity Hospital, 10000, Zagreb, Croatia.
Fröbe A; Department of Oncology and Nuclear Medicine, Sisters of Charity Hospital, 10000, Zagreb, Croatia.
Skala K; Centre for Informatics and Computing, Rudjer Boskovic Institute, 10000, Zagreb, Croatia.
Vrljičak A; Department of Oncology and Nuclear Medicine, Sisters of Charity Hospital, 10000, Zagreb, Croatia.
Medved Rogina B; Centre for Informatics and Computing, Rudjer Boskovic Institute, 10000, Zagreb, Croatia.
Kolarek B; Centre for Informatics and Computing, Rudjer Boskovic Institute, 10000, Zagreb, Croatia.
Bojović V; Centre for Informatics and Computing, Rudjer Boskovic Institute, 10000, Zagreb, Croatia.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Aug 13; Vol. 14 (1), pp. 18824. Date of Electronic Publication: 2024 Aug 13.
Typ publikacji:: Journal Article
MeSH Terms:: Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Proof of Concept Study ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; Computational Biology/methods

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.
Autorzy:: Venkadakrishnan VB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Presser AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Singh R; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Booker MA; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.
Traphagen NA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Weng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Boston College, Chestnut Hill, MA, USA.
Voss NCE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belmont Hill School, Belmont, MA, USA.
Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Mizuno K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Puca L; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Idahor O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard University, Cambridge, MA, USA.
Ku SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Bakht MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Borah AA; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Urology, University of California at San Francisco, San Francisco, CA, USA.; Arc Institute, Palo Alto, CA, USA.
Herbert ZT; Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, MA, USA.
Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.
Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rickman DS; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. himisha_.; Harvard Medical School, Boston, MA, USA. himisha_.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA. himisha_.; Pokaż więcej
Źródło:: Nature communications [Nat Commun] 2024 Aug 08; Vol. 15 (1), pp. 6779. Date of Electronic Publication: 2024 Aug 08.
Typ publikacji:: Journal Article
MeSH Terms:: Enhancer of Zeste Homolog 2 Protein*/metabolism
Enhancer of Zeste Homolog 2 Protein*/genetics
Gene Expression Regulation, Neoplastic*
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
Male ; Humans ; Cell Line, Tumor ; Animals ; Adenocarcinoma/genetics ; Adenocarcinoma/metabolism ; Adenocarcinoma/pathology ; Drug Resistance, Neoplasm/genetics ; Cell Differentiation ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Mice ; Cell Lineage

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 11.

Tytuł:: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Autorzy:: Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey. Electronic address: .
van den Bergh RCN; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Briers E; Patient advocate, Hasselt, Belgium.
Van den Broeck T; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Brunckhorst O; Department of Urology, King's College London, London, UK.
Darraugh J; European Association of Urology, Arnhem, The Netherlands.
Eberli D; Department of Urology, University Hospital Zurich, Zurich, Switzerland.
De Meerleer G; Department of Radiation Oncology, University Hospital Leuven, Leuven, Belgium.
De Santis M; Department of Urology, Universitätsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
Farolfi A; Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Gandaglia G; Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Gillessen S; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
Grivas N; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Henry AM; Leeds Cancer Centre, St. James's University Hospital and University of Leeds, Leeds, UK.
Lardas M; Department of Urology, Metropolitan General Hospital, Athens, Greece.
J L H van Leenders G; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Liew M; Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK.
Linares Espinos E; Department of Urology, University Hospital La Paz, Madrid, Spain.
Oldenburg J; Akershus University Hospital, Lørenskog, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Oprea-Lager DE; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.
Ploussard G; Department of Urology, La Croix du Sud Hospital, Toulouse, France.
Roberts MJ; Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland Centre for Clinical Research, Herston, Australia.
Rouvière O; Department of Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Université Lyon 1, UFR Lyon-Est, Lyon, France.
Schoots IG; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Schouten N; European Association of Urology, Arnhem, The Netherlands.
Smith EJ; European Association of Urology, Arnhem, The Netherlands.
Stranne J; Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital-Västra Götaland, Gothenburg, Sweden.
Wiegel T; Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.
Willemse PM; Department of Urology, Cancer Center University Medical Center Utrecht, Utrecht, The Netherlands.
Cornford P; Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK.; Pokaż więcej
Źródło:: European urology [Eur Urol] 2024 Aug; Vol. 86 (2), pp. 164-182. Date of Electronic Publication: 2024 Apr 29.
Typ publikacji:: Journal Article; Practice Guideline; Review
MeSH Terms:: Neoplasm Recurrence, Local*
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/therapy
Humans ; Male ; Neoplasm Metastasis ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/therapy ; Prostatic Neoplasms, Castration-Resistant/drug therapy

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 12.

Tytuł:: Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation.
Autorzy:: Dos Santos DZ; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, ON M5G 1L7, Canada.
Elbaz M; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, ON M5G 1L7, Canada; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Ain Helwan, Helwan, Cairo, Egypt.
Branchard E; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, ON M5G 1L7, Canada.
Schormann W; Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Brown CE; Krembil Research Institute, 60 Leonard Ave, Toronto, ON M5T 0S8, Canada.
Meek AR; Krembil Research Institute, 60 Leonard Ave, Toronto, ON M5T 0S8, Canada.
Njar VCO; Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; The Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA.
Hamilton RJ; Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Reed MA; Krembil Research Institute, 60 Leonard Ave, Toronto, ON M5T 0S8, Canada; Department of Pharmacology and Toxicology, Medical Sciences Building,1 King's College Circle, University of Toronto, M5S 1A8, Canada; Department of Chemistry, Lash Miller Building, 80 St. George Street, University of Toronto, Ontario M5S 3H6, Canada.
Andrews DW; Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada; Department of Biochemistry, University of Toronto, 27 King's College Cir, Toronto, ON M5S 1A1, Canada; Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, ON M5G 1L7, Canada.
Penn LZ; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, ON M5G 1L7, Canada. Electronic address: .; Pokaż więcej
Źródło:: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Aug; Vol. 177, pp. 116934. Date of Electronic Publication: 2024 Jun 17.
Typ publikacji:: Journal Article
MeSH Terms:: Sterol Regulatory Element Binding Protein 2*/metabolism
Sterol Regulatory Element Binding Protein 2*/genetics
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/pharmacology
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/metabolism
Male ; Humans ; Animals ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Mice ; Sterols/pharmacology ; Drug Synergism ; Mice, Nude ; Apoptosis/drug effects ; Cell Nucleus/metabolism ; Cell Nucleus/drug effects ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Cell Death/drug effects

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 13.

Tytuł:: Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023.
Autorzy:: Chiong E; Department of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore.
Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Buchan N; Department of Urology, Christchurch Public Hospital, Christchurch, New Zealand.; Monash University, Melbourne, Australia, Eastern Health, Melbourne, Australia.
Chen K; Department of Urology, Singapore General Hospital, Singapore, Singapore.
Chen SS; Department of Nursing, Tan Tock Seng Hospital, Singapore, Singapore.
Chua MLK; Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Hamid AR; Department of Urology, Faculty of Medicine Universitas Indonesia - CiptoMangunkusumo Hospital, Jakarta, Indonesia.
Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Khochikar M; Department of Urology/Uro-oncology, Ushakal Abhinav Institute of Medical Sciences, Sangli, India.
Letran J; Department of Urology, Chinese General Hospital and Medical Center, Manila, Philippines.
Lojanapiwat B; Department of Surgery, Chiang Mai University, Chiang Mai, Thailand.
Mallik I; Department of Radiation Oncology, Tata Medical Center, Kolkata, India.
Ng CF; SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
Ong TA; Department of Surgery, Universiti Malaya, Kuala Lumpur, Malaysia.
Poon DMC; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Pu YS; Department of Urology, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
Saad M; Department of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Schubach K; Monash University, Melbourne, Australia, Eastern Health, Melbourne, Australia.; Australian and New Zealand Urology Nurses (ANZUNS), Melbourne, Australia.
Takahara K; Department of Urology, Fujita Health University, Toyoake, Japan.
Tey J; Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Thang SP; Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore.
Toh PC; Department of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore.
Türkeri L; Department of Urology, Altunizade Hospital, Acibadem M.A. Aydinlar University, Istanbul, Turkey.
Vinh NT; Department of Urology, Binh Dan Hospital, Ho Chi Minh City, Vietnam.
Williams S; Monash University, Melbourne, Australia, Eastern Health, Melbourne, Australia.; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Davis ID; Lifehouse, Camperdown, Australia.; Pokaż więcej
Corporate Authors:: ANZUP Cancer Trials Group
Źródło:: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2024 Aug; Vol. 20 (4), pp. 481-490. Date of Electronic Publication: 2024 Apr 16.
Typ publikacji:: Journal Article
MeSH Terms:: Prostatic Neoplasms*/therapy
Prostatic Neoplasms*/pathology
Male ; Humans ; Asia/epidemiology ; Prostatic Neoplasms, Castration-Resistant/therapy ; Prostatic Neoplasms, Castration-Resistant/pathology

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 14.

Tytuł:: Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.
Autorzy:: Yin J; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Daryanani A; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.
Lu F; Department of Pharmacology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Ku AT; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Bright JR; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Alilin ANS; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.
Bowman J; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.
Lake R; Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Li C; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Truong TM; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Twohig JD; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Mostaghel EA; Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Ishikawa M; Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Simpson M; Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Trostel SY; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Corey E; Department of Urology, University of Washington, Seattle, Washington, USA.
Sowalsky AG; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Kelly K; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.; Pokaż więcej
Źródło:: The Prostate [Prostate] 2024 Aug; Vol. 84 (11), pp. 1033-1046. Date of Electronic Publication: 2024 May 06.
Typ publikacji:: Journal Article
MeSH Terms:: Bone Neoplasms*/secondary
Bone Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/genetics
Receptors, Androgen*/genetics
Receptors, Androgen*/metabolism
Animals ; Humans ; Male ; Mice ; Adenocarcinoma/pathology ; Adenocarcinoma/secondary ; Adenocarcinoma/metabolism ; Adenocarcinoma/genetics ; Carcinoma, Neuroendocrine/pathology ; Carcinoma, Neuroendocrine/metabolism ; Carcinoma, Neuroendocrine/genetics ; Disease Models, Animal ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/genetics

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 15.

Tytuł:: Evaluating the Therapeutic Effect of Hispidin on Prostate Cancer Cells.
Autorzy:: Chan KC; Graduate Institute of Cell Biology, College of Life Sciences, China Medical University, Taichung 40402, Taiwan.
Basavaraj P; Graduate Institute of Cell Biology, College of Life Sciences, China Medical University, Taichung 40402, Taiwan.
Tsai JC; Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 40402, Taiwan.
Viehoever J; International Master's Program of Biomedical, School of Medicine, China Medical University, Taichung 40402, Taiwan.
Hsieh BY; Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 40402, Taiwan.
Li XY; Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 40402, Taiwan.
Huang GJ; Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.; Department of Food Nutrition and Healthy Biotechnology, Asia University, Taichung 41354, Taiwan.
Huang WC; Graduate Institute of Cell Biology, College of Life Sciences, China Medical University, Taichung 40402, Taiwan.; International Master's Program of Biomedical, School of Medicine, China Medical University, Taichung 40402, Taiwan.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 18; Vol. 25 (14). Date of Electronic Publication: 2024 Jul 18.
Typ publikacji:: Journal Article
MeSH Terms:: Apoptosis*/drug effects
Cell Movement*/drug effects
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
Cell Proliferation*/drug effects
Humans ; Male ; Cell Line, Tumor ; Antineoplastic Agents/pharmacology ; Cell Cycle/drug effects ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Polyketides/pharmacology ; Polyketides/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.
Autorzy:: Weiten R; Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.; Department of Urology Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Koln, Germany.
Bernhardt M; Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Niemann M; Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
Kristiansen G; Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Grünwald V; Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany.
Ritter M; Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
Hölzel M; Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Alajati A; Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
Klümper N; Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.; Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Krausewitz P; Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.; Pokaż więcej
Źródło:: Journal of cellular and molecular medicine [J Cell Mol Med] 2024 Jul; Vol. 28 (14), pp. e18572.
Typ publikacji:: Journal Article
MeSH Terms:: Cell Adhesion Molecules*/metabolism
Cell Adhesion Molecules*/genetics
Antibodies, Monoclonal*/pharmacology
Antibodies, Monoclonal*/therapeutic use
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/genetics
Humans ; Male ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic/drug effects ; Immunoconjugates/pharmacology ; Immunoconjugates/therapeutic use ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Cell Proliferation/drug effects ; Nectins

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 17.

Tytuł:: Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy.
Autorzy:: Zhang D; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Ma B; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China. Electronic address: .
Liu D; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Wu W; Department of Neurosurgery, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Zhou T; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Gao Y; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Yang C; Department of the Operating Theater, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Jian Y; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Fan Y; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Qian Y; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Ma J; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Gao Y; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Chen Y; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Xu S; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Li L; Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China. Electronic address: .; Pokaż więcej
Źródło:: EBioMedicine [EBioMedicine] 2024 Jul; Vol. 105, pp. 105212. Date of Electronic Publication: 2024 Jul 01.
Typ publikacji:: Journal Article
MeSH Terms:: Proteolysis*/drug effects
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
E1A-Associated p300 Protein*/metabolism
Xenograft Model Antitumor Assays*
Peptides*/pharmacology
Peptides*/chemistry
Male ; Humans ; Animals ; Mice ; Cell Line, Tumor ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Disease Models, Animal ; Receptors, Androgen/metabolism ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Drug Discovery

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 18.

Tytuł:: Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
Autorzy:: Zhao F; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Zhao J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Wei X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Shi Y; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Xu N; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Zhu S; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Chen J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Sun G; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Dai J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Wang Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Zhang X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Liang J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Hu X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Liu H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Zhao J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Liu Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Nie L; Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Shen P; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Chen N; Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Zeng H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.; Pokaż więcej
Źródło:: The Prostate [Prostate] 2024 Jul; Vol. 84 (10), pp. 932-944. Date of Electronic Publication: 2024 Apr 17.
Typ publikacji:: Journal Article
MeSH Terms:: Ki-67 Antigen*/analysis
Ki-67 Antigen*/metabolism
Androstenes*/therapeutic use
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/metabolism
Biomarkers, Tumor*/metabolism
Biomarkers, Tumor*/analysis
Humans ; Male ; Aged ; Retrospective Studies ; Middle Aged ; Cell Proliferation/drug effects ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Treatment Outcome ; Predictive Value of Tests ; Progression-Free Survival ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 19.

Tytuł:: Role of MicroRNA-21 in Prostate Cancer Progression and Metastasis: Molecular Mechanisms to Therapeutic Targets.
Autorzy:: Singh VK; School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, VPO Kamand, Mandi, Himachal Pradesh, India.; Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, D.C., DC, USA.
Rajak N; Department of Medicinal Chemistry, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
Singh Y; Department of Urology, Faculty of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
Singh AK; University Department of Botany Lalit Narayan Mithila University, Darbhanga, Bihar, India.
Giri R; School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, VPO Kamand, Mandi, Himachal Pradesh, India.
Garg N; Department of Medicinal Chemistry, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India. .; Pokaż więcej
Źródło:: Annals of surgical oncology [Ann Surg Oncol] 2024 Jul; Vol. 31 (7), pp. 4795-4808. Date of Electronic Publication: 2024 May 17.
Typ publikacji:: Journal Article; Review
MeSH Terms:: MicroRNAs*/genetics
Disease Progression*
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/metabolism
Humans ; Male ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Neoplasm Metastasis ; Gene Expression Regulation, Neoplastic ; Prognosis

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 20.

Tytuł:: PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?
Autorzy:: Küper AT; Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Kersting D; Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Telli T; Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Herrmann K; Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Rominger A; Department of Nuclear Medicine, University Hospital Bern, University of Bern, Bern, Switzerland.
Afshar-Oromieh A; Department of Nuclear Medicine, University Hospital Bern, University of Bern, Bern, Switzerland.
Lopes L; Department of Nuclear Medicine, University Hospital Bern, University of Bern, Bern, Switzerland.; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Karkampouna S; Urology Research Laboratory, Department for BioMedical Research, University of Bern, 3008, Bern, Switzerland.; Department of Urology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Shi K; Department of Nuclear Medicine, University Hospital Bern, University of Bern, Bern, Switzerland.
Kim M; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.
Hadaschik B; Department of Urology and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Darr C; Department of Urology and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Umutlu L; Institute of Interventional and Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Fendler WP; Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Seifert R; Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Department of Nuclear Medicine, University Hospital Bern, University of Bern, Bern, Switzerland.; Pokaż więcej
Źródło:: Theranostics [Theranostics] 2024 Jun 11; Vol. 14 (9), pp. 3623-3633. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Positron Emission Tomography Computed Tomography*/methods
Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging
Prostatic Neoplasms, Castration-Resistant*/pathology
Humans ; Male ; Aged ; Middle Aged ; Follow-Up Studies ; Gallium Radioisotopes ; Retrospective Studies ; Aged, 80 and over ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology ; Glutamate Carboxypeptidase II/metabolism ; Radiopharmaceuticals ; Antigens, Surface/metabolism ; Gallium Isotopes ; Prognosis ; Lutetium/therapeutic use ; Positron-Emission Tomography/methods ; Tumor Burden ; Heterocyclic Compounds, 1-Ring/therapeutic use ; Dipeptides/therapeutic use

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Informacja

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat